GPI: A pan-cancer biomarker integrating genetic alterations, immune infiltration, and therapeutic response prediction
Wei Hu, Yu Gao, Zimu Li, Zelei Du, Jincheng Tao, Anastasios A Politis, Fulvio Vincenzo Grilli, Alessandro Di Stefano, Xiefeng Wang, Junxia Zhang, Jianxing Yin · 2026
Read GPI: A pan-cancer biomarker integrating genetic alterations, immune infiltration, and therapeutic response prediction by Wei Hu, Yu Gao, Zimu Li, Zelei Du, Jincheng Tao, Anastasios A Politis, Fulvio Vincenzo Grilli, Alessandro Di Stefano, Xiefeng Wang, Junxia Zhang, Jianxing Yin (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13598195.txt.
Description
Wei Hu and ten colleagues published a pan-cancer study in two thousand twenty-six on a sugar-processing enzyme called GPI. The enzyme sits in a core energy pathway and shows up in tumour growth. Its value as a marker across cancers was not fully mapped.
Database analyses found the enzyme raised in twenty-nine cancers and lowered in three. High levels tracked with advanced stage, spread, and poor survival. Its level also tied to stem-like traits, immune cell mixes, and likely drug responses. In brain tumour cells, boosting the enzyme sped growth and invasion; silencing it slowed both. The authors call GPI a candidate marker for diagnosis, outlook, and treatment choice, with more mechanism work needed.
Catalog record
| CREATOR | Wei Hu, Yu Gao, Zimu Li, Zelei Du, Jincheng Tao, Anastasios A Politis, Fulvio Vincenzo Grilli, Alessandro Di Stefano, Xiefeng Wang, Junxia Zhang, Jianxing Yin |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 76 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |